{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:53:31Z","timestamp":1785920011271,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.clinthera.2019.09.012","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T08:54:07Z","timestamp":1572857647000},"page":"2357-2379.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed\/Refractory Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"41","author":[{"given":"Claire","family":"Telford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaum M.","family":"Kabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarang","family":"Abhyankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.09.012_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.hemonc.2017.02.003","article-title":"Mantle cell lymphoma: contemporary diagnostic and treatment perspectives in the age of personalized medicine","volume":"10","author":"Sandoval-Sus","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.clinthera.2019.09.012_bib2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)65399-0","article-title":"Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization","volume":"154","author":"Li","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib3","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.09.012_bib4","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2019.09.012_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/17474086.2014.889561","article-title":"Risk factors for etiology and prognosis of mantle cell lymphoma","volume":"7","author":"Wang","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.09.012_bib7","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","article-title":"A\u00a0clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study","volume":"85","author":"Fisher","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.09.012_bib10","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib11","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib12","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.09.012_bib13","unstructured":"US Food and Drug Administration. TREANDA\u00ae (Bendamustine Hydrochloride) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022303lbl.pdf (Accessed October 2019)."},{"key":"10.1016\/j.clinthera.2019.09.012_bib14","unstructured":"US Food and Drug Administration. VELCADE (Bortezomib) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021602s044lbl.pdf (Accessed October 2019)."},{"key":"10.1016\/j.clinthera.2019.09.012_bib15","unstructured":"US Food and Drug Administration. REVLIMID (Lenalidomide) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021880s057lbl.pdf (Accessed October 2019)."},{"key":"10.1016\/j.clinthera.2019.09.012_bib16","unstructured":"US Food and Drug Administration. IMBRUVICA\u00ae (Ibrutinib) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/205552s028,210563s003lbl.pdf (Accessed October 2019)."},{"key":"10.1016\/j.clinthera.2019.09.012_bib17","unstructured":"US Food and Drug Administration. Rituxan (Rituximab) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103705s5457lbl.pdf (Accessed October 2019)."},{"key":"10.1016\/j.clinthera.2019.09.012_bib18","unstructured":"European Medicines Agency. Torisel 30 mg (Temsirolimus) Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/torisel-epar-product-information_en.pdf (Accessed October 2019)"},{"key":"10.1016\/j.clinthera.2019.09.012_bib19","unstructured":"US Food and Drug Administration. CALQUENCE\u00ae (Acalabrutinib) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf (Accessed October 2019)"},{"key":"10.1016\/j.clinthera.2019.09.012_bib20","unstructured":"European Medicines Agency. Acalabrutinib for the treatment of mantle cell lymphoma: public summary of opinion on orphan designation. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/16\/1625-public-summary-opinion-orphan-designation-acalabrutinib-treatment-mantle-cell-lymphoma_en.pdf (Accessed October 2019)"},{"key":"10.1016\/j.clinthera.2019.09.012_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2019.09.012_bib23","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1182\/blood-2018-99-110327","article-title":"Long-term follow-up of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma","volume":"132","author":"Wang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.09.012_bib24","unstructured":"National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013 Process and Methods Guides No. 92013."},{"key":"10.1016\/j.clinthera.2019.09.012_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib26","series-title":"NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data","author":"Latimer","year":"2011"},{"key":"10.1016\/j.clinthera.2019.09.012_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jrsm.25","article-title":"Network meta-analysis of parametric survival curves","volume":"1","author":"Ouwens","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.clinthera.2019.09.012_bib29","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.09.012_bib30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2019.09.012_bib31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trn\u011bn\u00fd","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.13456","article-title":"Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed\/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial","volume":"170","author":"Goy","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib35","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/10428194.2017.1357175","article-title":"Comparison of two doses of intravenous temsirolimus in patients with relapsed\/refractory mantle cell lymphoma","volume":"59","author":"Jurczak","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2019.09.012_bib36","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2019.09.012_bib37","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib38","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00277-015-2478-9","article-title":"Phase II study of bendamustine combined with rituximab in relapsed\/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings","volume":"94","author":"Czuczman","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib40","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib41","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2019.09.012_bib43","series-title":"Guidelines in Oncology (NCCN Guidelines) B-Cell Lymphomas Version 4.2018","year":"2018"},{"key":"10.1016\/j.clinthera.2019.09.012_bib44","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.09.012_bib45","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) Study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib46","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib47","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.09.012_bib48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2019.09.012_bib49","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V128.22.2977.2977","article-title":"Temsirolimus in combination with bendamustine and rituximab (BeRT) for the treatment of relapsed mantle cell and follicular lymphoma: final Phase I\/II results","volume":"128","author":"Hess","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.09.012_bib50","doi-asserted-by":"crossref","first-page":"A614","DOI":"10.1016\/j.jval.2014.08.2163","article-title":"Comparative effectiveness of treatments for relapsed or refractory mantle cell lymphoma (R\/R MCL), using matching adjusted indirect comparison","volume":"17","author":"Tongbram","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.09.012_bib51","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2019.09.012_bib52","article-title":"Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819304904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819304904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:36Z","timestamp":1758963096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819304904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0149291819304904"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.09.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed\/Refractory Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}